| Lapeyra, Olga |
NCT04641143: Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder |
|
|
| Recruiting | 3 | 700 | US | Troriluzole, Placebo | Biohaven Pharmaceuticals, Inc. | Obsessive-Compulsive Disorder | 12/24 | 12/24 | | |
NCT05628103: A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication |
|
|
| Completed | 3 | 101 | US | SEP-363856 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Schizophrenia | 04/24 | 04/24 | | |
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 568 | Europe, Canada, US | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 03/25 | 05/25 | | |
SICA 2, NCT05322941: Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD) |
|
|
| Active, not recruiting | 2 | 330 | US | AEF0117, 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one, Placebo oral capsule, Placebo | Aelis Farma, National Institute on Drug Abuse (NIDA) | Marijuana Abuse | 04/24 | 05/24 | | |
NCT06179108: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia |
|
|
| Recruiting | 2 | 350 | US | LB-102 | LB Pharmaceuticals Inc. | Schizophrenia | 10/24 | 01/25 | | |
NCT04933916: Study of EMB-001 as a Potential Smoking Cessation Treatment |
|
|
| Terminated | 1/2 | 16 | US | EMB-001 | Embera NeuroTherapeutics, Inc., Foundation for a Smoke Free World INC, Rose Research Center, LLC, Segal Trials | Tobacco Use Disorder | 04/23 | 05/23 | | |
NCT05848700: A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia |
|
|
| Completed | 1 | 60 | US | SEP-363856, Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | Schizophrenia | 03/24 | 03/24 | | |
NCT03788811: ERG Components in Schizophrenia and Bipolar Disorder Type I |
|
|
| Active, not recruiting | N/A | 300 | Canada, US, RoW | ERG assessment (RSPA) | diaMentis Inc. | Schizophrenia, Bipolar I Disorder | 12/24 | 12/24 | | |
| Smith, Adam |
NCT04641143: Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder |
|
|
| Recruiting | 3 | 700 | US | Troriluzole, Placebo | Biohaven Pharmaceuticals, Inc. | Obsessive-Compulsive Disorder | 12/24 | 12/24 | | |
| Recruiting | 3 | 375 | Europe, US, RoW | Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo | Suven Life Sciences Limited, Suven Life Sciences Ltd | Agitation, Alzheimer's Type Dementia | 01/25 | 01/25 | | |
NCT05439603: ANC-501 in the Treatment of Adults With Major Depressive Disorder |
|
|
| Active, not recruiting | 2 | 20 | US | ANC-501 | Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc. | Major Depressive Disorder | 09/23 | 11/23 | | |
NCT06179108: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia |
|
|
| Recruiting | 2 | 350 | US | LB-102 | LB Pharmaceuticals Inc. | Schizophrenia | 10/24 | 01/25 | | |
| Recruiting | N/A | 1600 | US | Obalon Navigation/Touch System | Obalon Therapeutics, Inc. | Obesity | 05/23 | 05/23 | | |
ARREST, NCT03872960: A Randomised Trial of Expedited Transfer to a Cardiac Arrest Centre for Non-ST Elevation Out-of-hospital Cardiac Arrest |
|
|
| Completed | N/A | 862 | Europe | Transfer to cardiac arrest centre | Guy's and St Thomas' NHS Foundation Trust, King's College London, London School of Hygiene and Tropical Medicine, Barts & The London NHS Trust, King's College Hospital NHS Trust, Imperial College Healthcare NHS Trust, Royal Brompton & Harefield NHS Foundation Trust, Royal Free Hospital NHS Foundation Trust, St George's University Hospitals NHS Foundation Trust, London Ambulance Service NHS Trust | Out-Of-Hospital Cardiac Arrest | 12/23 | 04/24 | | |
NCT06309784: Development of a Drill Guidance System to Aid Intra-operative Surgical Drilling |
|
|
| Recruiting | N/A | 30 | Europe | Drill Guidance System (DGS) | Royal United Hospitals Bath NHS Foundation Trust, University of Bath, Great Western Hospitals NHS Foundation Trust | Orthopaedic Surgery | 07/24 | 10/24 | | |
NCT05014165: Backtracking Leukemia-Typical Somatic Mutations in Cord Blood |
|
|
| Recruiting | N/A | 300 | US | Cord blood Sample Collection, Case identification and recruitment, Questionnaire Administration | Children's Oncology Group, National Cancer Institute (NCI) | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | 09/26 | 09/26 | | |
NCT01885299: RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT |
|
|
| Recruiting | N/A | 50000 | US, RoW | SRS/SBRT | The Radiosurgery Society, VisionTree | Neoplasms, Arteriovenous Malformation of Central Nervous System, Trigeminal Neuralgia | 12/30 | 12/30 | | |
| Deeb, Wissam |
EBS-101-TD-391, NCT06021522: A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder |
|
|
| Recruiting | 3 | 150 | Europe, Canada, US | Ecopipam, Ecopipam Hydrochloride | Emalex Biosciences Inc. | Tourette Syndrome | 11/24 | 03/27 | | |
| Recruiting | 3 | 196 | Europe, Canada, US, RoW | Ecopipam Hydrochloride | Emalex Biosciences Inc. | Tourette Disorder | 12/24 | 12/24 | | |
| Rajarethinam, Rajaprabhakaran |
NCT04641143: Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder |
|
|
| Recruiting | 3 | 700 | US | Troriluzole, Placebo | Biohaven Pharmaceuticals, Inc. | Obsessive-Compulsive Disorder | 12/24 | 12/24 | | |
EBS-101-TD-391, NCT06021522: A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder |
|
|
| Recruiting | 3 | 150 | Europe, Canada, US | Ecopipam, Ecopipam Hydrochloride | Emalex Biosciences Inc. | Tourette Syndrome | 11/24 | 03/27 | | |
| Recruiting | 3 | 196 | Europe, Canada, US, RoW | Ecopipam Hydrochloride | Emalex Biosciences Inc. | Tourette Disorder | 12/24 | 12/24 | | |
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 568 | Europe, Canada, US | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 03/25 | 05/25 | | |
UNCOVER, NCT04753385: The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes |
|
|
| Active, not recruiting | N/A | 300 | US | | LivaNova | Treatment Resistant Depression | 10/24 | 10/24 | | |
| Szczesniak, Amanda |
UNCOVER, NCT04753385: The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes |
|
|
| Active, not recruiting | N/A | 300 | US | | LivaNova | Treatment Resistant Depression | 10/24 | 10/24 | | |
| Nisar, Mohammad Asim |
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 568 | Europe, Canada, US | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 03/25 | 05/25 | | |
| Active, not recruiting | 3 | 1083 | Canada, US, RoW | Simufilam, PTI-125, Placebo | Cassava Sciences, Inc., Premier Research Group plc | Alzheimer Disease | 05/25 | 05/25 | | |
| Kjorvestad, Tyler |
NCT06085937: Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department |
|
|
| Recruiting | 1 | 50 | US | Ketamine | Lindsay Maguire, MD | Suicide, Suicidal Ideation, Depression | 04/25 | 04/25 | | |
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression |
|
|
| Recruiting | N/A | 6800 | US | Vagus Nerve Stimulation (VNS), VNS | LivaNova | Treatment Resistant Depression | 02/28 | 12/30 | | |
| Corzo, Melissa |
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 568 | Europe, Canada, US | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 03/25 | 05/25 | | |
